TP53 and small cell lung carcinoma: From a genomic perspective, comprehensive whole-exome or whole-genome sequencing of SCLC has demonstrated only universal mutations in TP53 and RB1. Moreover, unlike LUAD, no genetic subtypes of SCLC and no revolutionized specific therapeutic vulnerabilities have been identified [16, 36, 37, 75].